Table 1 Proportion of Asian patients enrolled in randomized controlled trials of DOACs
Study | Treatment | Total population N | Asians N (%) |
|---|---|---|---|
RCTs for treatment of VTE | |||
RE-COVER (41) | Dabigatran vs. standard care | 2539 | 65 (2.6%) |
RE-COVER II (43) | Dabigatran vs. standard care | 2589 | 537 (20.7%) |
EINSTEIN-DVT (44) | Rivaroxaban vs. standard care | 3449 | 494 (14.3%) |
EINSTEIN-PE (45) | Rivaroxaban vs. standard care | 4832 | 287 (5.9%) |
AMPLIFY (46) | Apixaban vs. standard care | 5395 | NR |
Hokusai-VTE (47) | Edoxaban vs. standard care | 8240 | 1727 (21.0%) |
RCTs for treatment of cancer-associated VTE | |||
Hokusai-VTE Cancer (50) | Edoxaban vs. standard care | 1046 | NR |
SELECT-D (51) | Rivaroxaban vs. standard care | 406 | < 15 (< 4%)a |
CARAVAGGIO (52) | Apixaban vs. edoxaban | 1155 | NR |
ADAM VTE (53) | Apixaban vs. standard care | 300 | 2 (0.7%) |